809 abstracts found.



Results filter

K-ras 146, N-ras 12/13, and N-ras 61 mutations in Quasar1 stage II/III colorectal cancers occur in 6% of cases.  A small but important group?

Year:

Session type:

Katie Southward1, Morag Taylor1, Kelly Handley2, Laura Magill2, Phil Chambers1, Claire Beaumont1, Susan Richman1, Matt Seymour3, David Kerr4, Richard Gray2, Phil Quirke1
1Leeds Institute of Molecular Medicine, Leeds, UK, 2Birmingham Clinical Trials Unit, Birmingham, UK, 3Cancer Research UK Clinical Centre, Leeds, UK, 4Department of Clinical Pharmacology, Oxford, UK

Imaging the development of functional tumour vasculature in vivo in preclinical models

Year:

Session type:

Gemma Marston1, Nicola Ingram1, Mark Hull1, Alex Markham1, Pam Jones1, P. Louise Coletta1
1University of Leeds, Leeds, UK

Defining a spatially restricted aPKC/ERK phosphoproteome

Year:

Session type:

Nick Peel1, Carine Rosse1, Katrina Boeckeler1, Peter Parker1
1CR-UK London Research Institute, London, UK

Analysing paired array-comparative genomic hybridisation and gene expression microarray data: A novel method to infer gene relationships

Year:

Session type:

Xin Yi Goh1,2, Richard Newton3, Lorenz Wernisch3, Rebecca Fitzgerald1
1MRC Cancer Cell Unit, Cambridge, UK, 2University of Cambridge, Cambridge, UK, 3MRC Biostatistics Unit, Cambridge, UK

Patient-specific mathematical radiation oncology: Integrating clinical imaging and modeling to improve outcomes

Year:

Session type:

Kristin Swanson1
1University of Washington, Seattle, WA, USA

Introduction: Genomics analysis of intratumour heterogeneity and drug resistance mechanisms in cancer medicine

Year:

Session type:

Charles Swanton1
1CR-UK London Research Institute, London, UK

Breast cancer intratumour heterogeneity: A challenge for personalised medicine

Year:

Session type:

James Hicks1
1Cold Spring Harbor Laboratory

Dissecting mechanisms of cancer drug resistance through functional genetics

Year:

Session type:

Rene Bernards1
1Netherlands Cancer Institute, Amsterdam, The Netherlands

Intratumoural heterogeneity and the evolution of drug resistance in high-grade serous ovarian cancer

Year:

Session type:

James Brenton1
1Cancer Research UK Cambridge Research Institute, Cambridge, UK

Introduction: Genetic predisposition to cancers – future implications for selective screening, surveillance and management

Year:

Session type:

Ros Eeles1
1ICR, Sutton, UK

Predicting cancer risk using genetic variation

Year:

Session type:

Douglas Easton1
1University of Cambridge, Cambridge, UK

Genetic predisposition to cancer – implications for selective screening

Year:

Session type:

Harry de Koning1
1Erasmus MC & Johns Hopkins Bloomberg School of Public Health, Rotterdam, The Netherlands

Using germline susceptibility testing to inform the treatment of newly-diagnosed cancer patients

Year:

Session type:

Mark Robson1
1Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Introduction: Genomic instability and cancer: Lessons from analysis of Bloom’s syndrome

Year:

Session type:

Ian Hickson1
1University of Copenhagen, Copenhagen, Denmark

Regulation of recombination-mediated DSB repair and its importance for genome stability

Year:

Session type:

Stephen West1
1London Research Institute, South Mimms, UK

The human mismatch repair interactome

Year:

Session type:

Josef Jiricny1
1Institute of Molecular Cancer Research, Zurich, Switzerland

The BRCA1-BRCA2 pathway of homologous recombination

Year:

Session type:

Simon Powell1
1Memorial Sloan-Kettering, New York, USA

Introduction: Lung cancer treatment: We have lift off!

Year:

Session type:

Marianne Nicolson1
1Aberdeen Royal Infirmary, Aberdeen, UK

Population-based data on lung cancer from the UK: The National Audit and beyond

Year:

Session type:

Michael Peake1
1Glenfield Hospital, Leicester, UK

Modern radiotherapy techniques and progress in non-small cell lung cancer

Year:

Session type:

Suresh Senan1
1VU University Medical Center, Asterdam, The Netherlands

Aberrant cell signalling in cancer

Year:

Session type:

Chris Marshall1
1Institute of Cancer Research, London, UK

Stratified medicine in colorectal cancer: Current state and challenges ahead

Year:

Session type:

Sabine Tejpar1
1Digestive Oncology and Center for Human Genetics, University Hospital Leuven, Leuven, Belgium

Evolution of the cancer genome

Year:

Session type:

Michael R. Stratton1
1Wellcome Trust Sanger Institute, Cambridge, UK

Introduction: The first century of human tumour virology

Year:

Session type:

Chris Boshoff1
1University College London Cancer Institute

Lessons from the small DNA tumour viruses

Year:

Session type:

Daniel DiMaio1
1Yale University School of Medicine, New Haven, CT, USA

Mechanisms of human papillomavirus-induced malignancy

Year:

Session type:

Lawrence Banks1
1International Centre for Genetic Engineering and Biotechnology, Trieste, Italy

Mechanisms of Epstein-Barr virus lymphomagenesis

Year:

Session type:

Martin Rowe1
1University of Birmingham, Birmingham, UK

Introduction: Deregulated expression of the translation machinery in cancer

Year:

Session type:

Robert White1
1Beatson Institute for Cancer Research, Glasgow, UK

Translating the PI3K/mTOR pathway and translational control to radiation therapy

Year:

Session type:

Robert Schneider1
1New York, NY, New York, NY, USA

Translational control of pancreatic carcinogenesis

Year:

Session type:

Stéphane Pyronnet1
1INSERM U1037, Toulouse, France

Deregulation of gene expression at the level of translation in diffuse large B-cell lymphoma

Year:

Session type:

Anne Willis1
1MRC Toxicology Unit, Leicester, UK

Introduction: Biomarker validation and adaptive clinical trial design

Year:

Session type:

Caroline Dive1
1Paterson Institute for Cancer Research, Manchester, UK

Fit-for-purpose biomarker validation

Year:

Session type:

Howard Scher1
1Memorial Sloan-Kettering Cancer Center

Biomarkers in early drug development

Year:

Session type:

Josep Tabernero1
1Val d'Hebron University Hospital, Barcelona, Spain

Adaptive trial design that incorporates biomarkers

Year:

Session type:

Lucinda Billingham1
1MRC Midland Hub for Trials Methodology Research & Cancer Research UK Clinical Trials Unit, University of Birmingham

Introduction: Cancer awareness and early diagnosis: International perspectives

Year:

Session type:

Amanda Ramirez1
1King's College London, London, UK

International differences in cancer awareness and beliefs: The International Cancer Benchmarking Partnership

Year:

Session type:

Lindsay Forbes1
1King's College London, London, UK

Cancer awareness and early diagnosis in Denmark: A rewarding intervention?

Year:

Session type:

Peter Vedsted1
1Research Centre for Cancer Diagnosis in Primary Care, Aarhus University, Denmark

Public attitudes and awareness of cancer risks and early detection: a Canadian perspective

Year:

Session type:

Heather Bryant1
1Canadian Partnership Against Cancer, Toronto, ON, Canada

Introduction: Clinical and translational approaches to radiotherapy

Year:

Session type:

Gillie McKenna1
1Gray Institute for Radiation Oncology & Biology, University of Oxford, Oxford, UK

Strategies for radiosensitisation targetting the tumour microenvironment

Year:

Session type:

Ruth Muschel1
1University of Oxford, Oxford, UK

The role of functional imaging in developing strategies towards a patient-tailored approach in prostate cancer

Year:

Session type:

Karin Haustermans1
1University Hospital, Leuven, Belgium

Promising new drugs in lymphoma – opportunities for changing practice

Year:

Session type:

Bruce D. Cheson1
1Georgetown Lombardi Comprehensive Cancer Center, Washington, USA

Reduced intensity allogeneic transplantation for relapsed lymphoma

Year:

Session type:

Stephen Mackinnon1
1University College Hospital, London, UK

Late treatment effects in patients with lymphoma – their impact on the duration and quality of survival

Year:

Session type:

Flora van Leeuwen1
1The Netherlands Cancer Institute

Introduction:  Liver and colorectal cancer

Year:

Session type:

Tim Maughan1
1Gray Institute for Radiation Oncology and Biology, Oxford, UK

The tumour vasculature in metastatic CRC: Beyond the obvious

Year:

Session type:

Lee Ellis1
1MD Anderson Cancer Center, Houston, Texas, USA

Exploiting knowledge of DNA damage repair to improve treatment for patients with colorectal cancer

Year:

Session type:

Ricky Sharma1
1University of Oxford, Oxford, UK

Molecular selection of therapy in colorectal cancer: Clinical trials

Year:

Session type:

Richard Wilson1
1Queen's University Belfast

Introduction: Paediatric oncology: Survivorship from Childhood Cancer

Year:

Session type:

Adam Glaser1
1St James's Hospital, Leeds, UK